Nadia B. Hassounah - Concepedia

Author

Nadia B. Hassounah

University of Arizona ORCID

Also Known As

Hassounah, Nadia B., N. Hassounah, N.B. Hassounah, Nadia B Hassounah, Nadia B. Hassounah, Nadia Hassounah

Publications

671

Citations

H-Index

Concepts

All Affiliations

University of Arizona University of Arizona Cancer Center University of Washington Novartis (United States)

About

Nadia B. Hassounah is an author at University of Arizona specializing in pathology, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	254
2	Pathology	4	4	254
3	Cell Biology	3	3	243
4	Health Sciences	1	1	11
5	Immunology	1	1	11

Nadia B. Hassounah

Publications

627

Citations

H-Index

Page 1

	Year	Citations
Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on Hedgehog Signaling Nadia B. Hassounah, Thomas A. Bunch, Kimberly M. McDermott Clinical Cancer Research	2012	155
Loss of primary cilia occurs early in breast cancer development Ina Menzl, Lauren LeBeau, Ritu Pandey, Cilia	2014	145
Primary Cilia Are Lost in Preinvasive and Invasive Prostate Cancer Nadia B. Hassounah, Ray B. Nagle, Kathylynn Saboda, PLoS ONE UrologySignaling PathwayGenitourinary CancerMedicinePathology	2013	139
Identification and characterization of an alternative cancer-derived PD-L1 splice variant Nadia B. Hassounah, Venkat S. Malladi, Yi Huang, Cancer Immunology Immunotherapy OncologyOncogenic AgentMedicinePathologyCancer Genomics	2018	82
Inhibition of Ciliogenesis Promotes Hedgehog Signaling, Tumorigenesis, and Metastasis in Breast Cancer Nadia B. Hassounah, Martha Nuñez, Colleen Fordyce, Molecular Cancer Research	2017	51
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer Vũ Quốc Huy Nguyễn, Cristy Loustaunau, Alexander Facista, Journal of Visualized Experiments PathologyCancer BiologyTumor BiologyField DefectsMolecular Pathology	2010	22
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors Rom S. Leidner, Kevin C. Conlon, Douglas G. McNeel, Journal for ImmunoTherapy of Cancer	2023	22
Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors Giuseppe Curigliano, M. Martín Jiménez, Toshio Shimizu, Cancer Research ImmunologyPathologyImmunotherapeuticsCd4 T Cell ResponsesImmunotherapy	2021	11

Page 1